Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long‐term aplastic anemia treatment

Abstract

Key Clinical Message Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia–paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors. Ravulizumab treatment for PNH before HSCT might have a beneficial effect.

Keywords

• alternative donor
• aplastic anemia–paroxysmal nocturnal hemoglobinuria syndrome
• haploidentical hematopoietic stem cell transplantation
• posttransplant cyclophosphamide
• ravulizumab